학술논문
Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041